Shionogi, Inc

F2G raises $100M to complete Phase 3 testing of olorofim, a novel antifungal for invasive aspergillosis, after FDA rejection. AMR Action Fund and ICG co-led the funding, joined by eight other investors. F2G aims to address FDA concerns and prepare for U.S. launch.

The article highlights 2024 trends in drug innovation, including advancements in gene and cell therapies, AI in drug discovery, and the rise of patient-centric R&D. It also covers the evolution of clinical trials towards decentralization and inclusivity, emphasizing the importance of technology and patient voices in shaping future treatments.

Pharma's 2024 outlook highlights advancements in gene and cell therapies, AI in drug development, and patient-centric R&D. Innovations like CRISPR, mRNA vaccines, and treatments for obesity, aging, and tough-to-treat cancers are set to transform healthcare. Regulatory shifts and DEI in clinical trials aim for more inclusive and efficient drug development.

Over 20 drugmakers from Japan, the U.S., and Europe, including Eisai, Amgen, and Novartis, launched a $1 billion+ fund to support startups tackling antibiotic-resistant infections, with WHO and European Investment Bank participation.